NASDAQ:ABVC
ABVC BioPharma, Inc. Stock News
$0.94
-0.0935 (-9.09%)
At Close: May 24, 2024
Stocks That Hit 52-Week Lows On Friday
04:05pm, Friday, 24'th Jun 2022 Benzinga
On Friday, 61 companies hit new 52-week lows.
Areas of Interest About Today's 52-Week Lows:
Ecopetrol (NYSE:EC) was the biggest company in terms of market cap to set a new 52-week low.
ThermoGenesis
ABVC BioPharma Submitted Vitargus® Phase II Study Plan to Australia HREC
12:30pm, Thursday, 16'th Jun 2022 GlobeNewswire Inc.
FREMONT, CA, June 16, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hemat
ABVC BioPharma Announces Termination of Two Contracts
12:30pm, Friday, 10'th Jun 2022 GlobeNewswire Inc.
FREMONT, CA, June 10, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hemat
ABVC BioPharma Announces Enrollment Progress for ADHD Phase II Part 2 Clinical Study
12:30pm, Wednesday, 01'st Jun 2022 GlobeNewswire Inc.
FREMONT, CA, June 01, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hemat
ABVC BioPharma Engaged by Orion BioTech to Identify Global Licensing Partners
12:30pm, Wednesday, 25'th May 2022 GlobeNewswire Inc.
FREMONT, CA, May 25, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hemato
Prestigious Researchers to Provide Consulting Services in Connection with ABVC BioPharma's Depression Medicines
11:30am, Monday, 23'rd May 2022 GlobeNewswire Inc.
Fremont, CA, May 23, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hemat
ABVC Biopharma Reports First Quarter 2022 Financial and Operational Results
09:46pm, Monday, 16'th May 2022 GlobeNewswire Inc.
FREMONT, CA, May 16, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire--ABVC BioPharma, Inc. (Nasdaq: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematolo
ABVC BioPharma Engages the FreeMind Group to Support Grant Funding
12:30pm, Friday, 13'th May 2022 GlobeNewswire Inc.
FREMONT, CA, May 13, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hemato
ABVC BioPharma Completes Site Initiation Visits and Begins Enrollments for ADHD Phase II Part 2 Clinical Study
12:30pm, Thursday, 28'th Apr 2022 GlobeNewswire Inc.
FREMONT, CA, April 28, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire - ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hemato
ABVC BioPharma Announces Vitargus Phase II Clinical Study Investigator Meeting
12:30pm, Tuesday, 26'th Apr 2022 GlobeNewswire Inc.
FREMONT, CA, April 26, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/he
ABVC Biopharma Announces Fiscal Year 2021 Financial and Operational Results
08:18pm, Thursday, 31'st Mar 2022 GlobeNewswire Inc.
FREMONT, CA, March 31, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (Nasdaq: ABVC), a biotechnology company specializing in botanically based solutions that seeks to deliver h
ABVC BioPharma to Present at the Maxim Group 2022 Virtual Growth Conference
01:25pm, Wednesday, 23'rd Mar 2022 GlobeNewswire Inc.
Fremont, CA, March 23, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hem
ABVC BioPharma to Present at the Maxim Group 2022 Virtual Growth Conference
09:25am, Wednesday, 23'rd Mar 2022
Fremont, CA, March 23, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hema
ABVC BioPharma Announces Principal Investigator Meeting for Phase II Part 2 ADHD Clinical Study
01:00pm, Wednesday, 02'nd Feb 2022 GlobeNewswire Inc.
Fremont, CA, Feb. 02, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hemato
ABVC BioPharma Selects Additional Vitargus® Phase II Study Sites
01:30pm, Wednesday, 05'th Jan 2022 GlobeNewswire Inc.
Thailand Sites Join Australian Sites Confirmed to Participate in the Study
